Research priorities to move ctDNA assays into clinical decision making in early-stage breast cancer

Circulating tumor DNA (ctDNA)-based Minimal Residual Disease (MRD) assays are increasingly utilised in early-stage breast cancer; but evidence for decision-making remains incomplete. The Breast International Group (BIG) and National Clinical Trials Network (NCTN) ctDNA working group identified research priorities to advance these assays toward clinical utility: clinical trial designs proving utility and affordability; validating ctDNA dynamics as surrogate endpoint; standardising assays; and evaluating patient-reported outcomes and equity. Prospective, randomised evidence remains essential before implementation.

Authors

Institutions

Publication Details

Journal
npj Breast Cancer
Published
2026-10-22
DOI
https://doi.org/10.1038/s41523-026-01063-3
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Research priorities to move ctDNA assays into clinical decision making in early-stage breast cancer

David Cameron, E. Shelley Hwang, Séamus O’Reilly, NU Lin et al.
npj Breast Cancer
Cancer Genomics and Diagnostics
article

Research priorities to move ctDNA assays into clinical decision making in early-stage breast cancer

David Cameron, E. Shelley Hwang, Séamus O’Reilly, NU Lin, gabriele zoppoli, Catherine Alix‐Panabières, Stefania Morganti, David W. Cescon, Michail Ignatiadis, Mariya Rozenblit, Eric Winer, Angela De Michele, Heather Parsons, Philippe Bedard, Antonio Wolff, Maria Coakley, Yara Abdou
article en

Abstract

Circulating tumor DNA (ctDNA)-based Minimal Residual Disease (MRD) assays are increasingly utilised in early-stage breast cancer; but evidence for decision-making remains incomplete. The Breast International Group (BIG) and National Clinical Trials Network (NCTN) ctDNA working group identified research priorities to advance these assays toward clinical utility: clinical trial designs proving utility and affordability; validating ctDNA dynamics as surrogate endpoint; standardising assays; and evaluating patient-reported outcomes and equity. Prospective, randomised evidence remains essential before implementation.

npj Breast Cancer
University of North Carolina at Chapel Hill (US), BC Cancer Agency (CA), Harvard University (US), Johns Hopkins University (US), Duke University (US), Institut Jules Bordet (BE), Princess Margaret Cancer Centre (CA), Yale University (US), Fred Hutch Cancer Center (US), Centre Hospitalier Universitaire de Montpellier (FR), Cancer Trials Ireland (IE), Dana-Farber Cancer Institute (US), Duke Cancer Institute, Canadian Cancer Trials Group (CA), University of Pennsylvania (US), University of Genoa (IT), University of Edinburgh (GB)
Openalex Percentile: Top 19%
Cancer Genomics and Diagnostics
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon